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Background
Bio-pharmaceutical industries face an increasing
demand to accelerate process development and reduce
costs. Indeed as technologies mature, pressure on cost
and timelines is greater for delivering scalable and
robust processes. Here we present a novel method in
order to speed up and interconnect clone selection with
cell culture process development and scale up to 80L
scale.
Materials and methods
Ambr™ 48 and 80L stirred tank bioreactor were run for
14 days in a fed-batch mode in a chemically defined
medium. A CHO cell line expressing a recombinant
monoclonal antibody (MAb) was used. Feed was added
daily from day 3 onwards. If required, antifoam C was
added to the bioreactor. DO, pH, and temperature were
controlled at setpoint. Viable cell concentration (VCC),
cell viability, and average cell diameter were measured
using a ViCell cell counter. Osmolality was obtained
using an Osmometer (Advanced Instruments). On har-
vest day, MAb concentration of the supernatant samples
was quantified using Protein A high performance liquid
chromatography. For the minibioreactors run, triplicates
were pooled on harvest day for product quality attri-
butes analysis. For both scales cell culture fluid samples
were centrifuged and filtered to remove cell debris. The
monoclonal antibody was purified by ÄKTAXpress (GE
Healthcare) Protein-A purification. The neutralized elu-
ate was used for product quality analysis.
Results
High throughput technologies enable us to interconnect
clone and process development thus reducing the risks
associated with early-stage process development while
reducing timelines and enabling us to achieve higher pro-
cess robustness in a leaner manner. In one ambr™48 run
different feeding strategies were assessed on 4 pre-
selected lead clones for selecting the final lead clone, the
fed-batch feeding strategy and additional data with feed
compositions all at once. The selected condition (clone,
type of feed and feeding strategy) was based on the maxi-
mization of the MAb titer and target High Molecular
Weight Species (HMWS) level and Acidic Peak Group
(APG) level (data not shown).
Scale up from ambr™ 48 to 80L stirred tank bioreac-
tor was performed with the selected clone, feed and
feeding strategy. Similar cell growth profiles were
obtained at ambr™ scale and 80L scale for the selected
condition (Figure 1).
Monoclonal Antibody titers and percentages of Acidic
Peak Group obtained at harvest day were comparable
between scales (Table 1). Process robustness was shown
by performing a number of 4 batches at 80L scale.
Conclusions
Selection of the lead clone together with the optimal
feeding strategy was performed in one single ambr™ run
and 16 conditions were tested in triplicate at the time of
clone selection, compared to conventional approaches
relying on 1L-10L stirred tank bioreactor experiments
run on a single lead clone. Scale up was achieved success-
fully thus enabling early material production for down-
stream, formulation and analytical development. In
conclusion, miniaturized bioreactors enabled us to inter-
connect clone and process design space selection and
enable immediate 80L production.
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Figure 1 Viable cell concentration comparison between
ambr™ and 80L scales (solid black line: 80L scale, dotted
black line: ambr™scale).
Table 1. MAbtiters and APG level obtained with the
selected clone, feed and feeding strategy on harvest day
at ambr™ and 80L scales
MAb titer (Normalized) APG (Normalized)
ambr™ (n = 3) 0.9 0.7
80L (n = 4) 0.8 0.7
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